ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Our products for these growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

http://www.ecoanimalhealthgroupplc.com/

12 Dec
Peel Hunt
575.00
Buy
12 Dec
N+1 Singer
N/A
Corporate

Regulatory Approval
BUS
Regulatory Approval
Eco Animal Health Group Plc

9 January 2017
ECO Animal Health Group plc
(AIM: EAH)
ECO RECEIVES MEXICAN MARKETING AUTHORISATION FOR AIVLOSIN FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION
ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health de Mxico has received a marketing authorisation from the Secretariat of Agriculture, Livestock, Rural Development, Fisheries and Food (SAGARPA) of the Government of Mexico for the use of Aivlosin 625 mg/g water soluble granules in chickens laying eggs for human consumption.
This approval, the first in Latin America following the European approval in June 2016, will allow ECO to start selling Aivlosin in Mexico for the medication of drinking water for the treatment of infections caused by Mycoplasma in poultry laying eggs for human consumption with a zero day drug withdrawal period for eggs.
Aivlosin, ECOs patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.
Peter Lawrence, Chairman of ECO, commented This approval from the Mexican authorities is an important step in the development of Aivlosin for commercial layers with Mexico being the worlds fourth largest egg producing country. ECO has begun the process of submitting the Aivlosin regulatory files for the treatment of layers in numerous other key egg producing markets. It underlines ECOs continued commitment to being a major force in the international market for veterinary pharmaceutical products

9 Jan
Peel Hunt
575.00
Buy
9 Jan
N+1 Singer
N/A
Corporate

Holding(s) company >14%

Trading Statement
BUS
Trading Statement
Eco Animal Health Group Plc

Eco Animal Health Group plc (the "Group")
Trading statement
ECO Animal Health Group plc, the international producer of animal health pharmaceuticals, is releasing a trading statement in relation to its results for the year ended 31 March 2017.
The Group is likely to exceed the market expectations for revenue and significantly exceed the market expectations for pre-tax profit for the year ended 31 March 2017.
The announcement of the full results for the year to 31 March 2017 is anticipated to be released on 30 June 2017.

09:10 15/05/2017
Broker Forecast - Peel Hunt issues a broker note on Eco Animal Health Group PLC
Peel Hunt today reaffirms its buy investment rating on Eco Animal Health Group PLC (LON:EAH) and raised its price target to 650p (from 575p). Story provided by StockMarketWire.com

Final Results
BUS
Final Results
Eco Animal Health Group Plc


30 June 2017
ECO Animal Health Group plc (ECO)
(AIM: EAH)
Results for the year ended 31 March 2017
ECO ANIMAL HEALTH REPORTS ANOTHER STRONG PERFORMANCE
HIGHLIGHTS
Financials
30% increase in sales to 61.4m (2016: 47.1m)
44% increase in gross profit to 30m (2016: 21.0m) on improved margin
75% increase in pre-tax profit to 13.5m (2016: 7.7m)
54% increase in adjusted EBITDA to 17.1m (2016: 11.1m)
21% increase in second interim dividend to 4.6p (2016: 3.8p) making total dividend for the year up 25% to 7.1p (2016: 5.7p)
Strong cash generation from operations leaving net cash of 21.0 million at year end
Operations
Demand for Aivlosin continues to grow strongly
Strong performances in all major geographic areas, bar Brazil
New marketing authorisations gained in Europe, Brazil, Mexico and Thailand
Continued investment in new routes to market, product development, people and stockholding to support future growth
Peter Lawrence, Executive Chairman of ECO Animal Health Group plc, commented:
ECO has started the current year strongly with revenue ahead of the previous year. The ongoing weakness in the value of sterling may continue to be of benefit to ECO as virtually all our sales and the majority of costs arise locally in dollars, RMB or the euro. The business is robust with a sound, debt free balance sheet and this coupled with our strong cash generation will allow us to capitalise on market opportunities as they arise. We look forward with confidence.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations.

10:40 30/06/2017
Broker Forecast - Peel Hunt issues a broker note on Eco Animal Health Group PLC
Peel Hunt today reaffirms its buy investment rating on Eco Animal Health Group PLC (LON:EAH) and raised its price target to 725p (from 650p). Story provided by StockMarketWire.com

ECO gets US regulatory approval for Aivlosin
StockMarketWire.com
ECO Animal Health Group's subsidiary ECO Animal Health Limited has received a marketing authorisation for Aivlosin in the United States from the Center for Veterinary Medicine of the Food and Drug Administration.

Aivlosin, ECO's patented antimicrobial, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.

ECO said this authorisation was for the use of Aivlosin 625 mg/g water soluble granules in for the control of swine respiratory disease (SRD) associated with Bordetella bronchiseptica, Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis, four important bacterial respiratory pathogens of swine.

ECO said: "This new treatment meets all the guidelines for the responsible use of antimicrobials. Importantly, with global concerns about the use of antibiotics in food production animals, this treatment is under the control of veterinarians, is available under prescription only and has a low, highly effective therapeutic dose rate, short treatment duration and a zero day drug withholding period."

ECO aid the product would be marketed through Pharmgate Animal Health LLC, the group's well-established sales and marketing joint venture formed in 2010 with Pharmgate LLC, the majority-owned US subsidiary of Jinhe Biotechnology Co. Ltd. in China.

ECO chairman Peter Lawrence said: "We are extremely pleased to receive this second marketing authorisation for the Aivlosin water soluble granules formulation in the United States.

"The swine respiratory disease segment is a key one and this latest approval demonstrates ECOs continued progress to becoming a major force in the international market for veterinary pharmaceutical products."



Story provided by StockMarketWire.com

Regulatory Approval
BUS
Regulatory Approval
Eco Animal Health Group Plc

ECO Animal Health Group plc
(AIM: EAH)
ECO RECEIVES CANADIAN MARKETING AUTHORISATION FOR AIVLOSIN FOR SWINE RESPIRATORY DISEASE
ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation for Aivlosin in Canada from the Veterinary Drugs Directorate of Health Canada.
Aivlosin, ECOs patented antimicrobial, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.
This authorisation is for the use of Aivlosin 625 mg/g water soluble granules for swine respiratory disease (SRD) associated with Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis, three important bacterial respiratory pathogens of swine.
This new treatment meets all the guidelines for the responsible use of antimicrobials. Importantly, with global concerns about the use of antibiotics in food production animals, this treatment is under the control of veterinarians, is available under prescription only and has a low, highly effective therapeutic dose rate, short treatment duration and a zero day drug withholding period.
The product will be marketed through Pharmgate Animal Health Canada Inc. our well-established sales and marketing joint venture formed in 2010 with Pharmgate LLC, the majority-owned U.S. subsidiary of Jinhe Biotechnology Co. Ltd. in China.
Peter Lawrence, Chairman of ECO, commented We are extremely pleased to receive this second marketing authorisation for the Aivlosin water soluble granules formulation in Canada, the seventh largest pork producing country in the world. The swine respiratory disease segment is a key one and this latest approval demonstrates ECOs continued progress to becoming a major force in the international market for veterinary pharmaceutical products.

Recovery underway?